Fig. 2. Human GRHL1-activating compounds and their impact on nematodal lifespan.

a Schematic Venn diagram of hits activating a human GRHL and/or NRF2 luciferase reporter with fold change ≥2 at 10 µM in the primary screening. Indicated are total number of hits and hits as percentage of full library (2560 compounds). See Supplementary Data 4. b Heat map depicting log2 fold change reporter activation in a three-point dose–response assay (5, 10, and 20 µM) of the top 15 GRHL hit compounds on the reporters as in (a), normalized to cell viability (n = 2–3 per condition). c–q Lifespan assays, all using WT (N2) nematodes treated with the respective individual compound at a concentration of 1 µM in plate and vs. DMSO control. Lifespan graphs contain percentage change of mean lifespan compound vs. DMSO control and P-values as determined by log-rank test. See Supplementary Data 1 for detailed lifespan assay statistics. Source data are provided as a Source data file.